Natera, Inc. (NASDAQ:NTRA) Insider Sells $149,837.04 in Stock

by · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 1,026 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $149,837.04. Following the completion of the transaction, the insider now directly owns 144,782 shares of the company’s stock, valued at $21,143,963.28. The trade was a 0.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

  • On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total value of $859,740.00.
  • On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $862,689.87.
  • On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Stock Up 3.1 %

Shares of NASDAQ NTRA opened at $150.87 on Thursday. The firm’s 50-day moving average price is $162.25 and its 200-day moving average price is $149.27. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $20.40 billion, a price-to-earnings ratio of -85.72 and a beta of 1.80. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Guggenheim boosted their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Robert W. Baird boosted their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Canaccord Genuity Group restated a “buy” rating and issued a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. Morgan Stanley boosted their price objective on shares of Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Finally, Piper Sandler boosted their price objective on shares of Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $178.12.

Read Our Latest Stock Analysis on NTRA

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Wellington Management Group LLP boosted its position in Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. Norges Bank acquired a new position in Natera during the fourth quarter worth about $224,040,000. Finally, Raymond James Financial Inc. acquired a new position in Natera during the fourth quarter worth about $146,419,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More